MedTrace Logo

Efficacy, Safety and Tolerability Study of TAK-583 in Subjects With Postherpetic Neuralgia

NCT00377598 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 399

Last updated 2012-02-02

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of TAK-583, once daily (QD), in relieving pain in subjects with postherpetic neuralgia.

Conditions

  • Neuralgia, Postherpetic

Interventions

DRUG

TAK-583

TAK-583 5 mg, tablets, orally, once daily for up to 8 weeks

DRUG

TAK-583

TAK-583 25 mg, tablets, orally, once daily for up to 8 weeks

DRUG

TAK-583

TAK-583 50 mg, tablets, orally, once daily for up to 8 weeks

DRUG

TAK-583

TAK-583 100 mg, tablets, orally, once daily for up to 8 weeks

DRUG

Placebo

TAK-583 placebo-matching tablets, orally, once daily for up to 8 weeks

Sponsors & Collaborators

Principal Investigators

  • VP Clinical Science · Takeda Global Research & Development Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • Australia
  • Bulgaria
  • Czechia
  • Germany
  • Netherlands
  • Poland
  • Russia
  • South Africa
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00377598 on ClinicalTrials.gov